Subcutaneous infliximab has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications for the IV formulation, including for the treatment of IBD in June 2020. During the United European Gastroenterology Week virtual 2020 held from October 11 to 13, a symposium is hosted by Celltrion Healthcare to review the latest clinical evidence for infliximab SC, explore bio-innovative approaches with biologic development, and discuss clinical practice of infliximab in the era of COVID-19.
|2020-04-13||Celltrion Group’s Statement on the development of a therapeutic antibody treatment to combat COVID-19||Celltrion Healthcare|
|2018-12-11||[Notice to shareholders] Celltrion Healthcare’s Statement on press release from YTN||Celltrion Healthcare|
|2018-11-19||Biosimilars have the potential to deliver dramatic cost savings for US and European healthcare systems||Celltrion Healthcare|
|2018-05-21||Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare||Celltrion Healthcare|
|2018-02-15||Celltrion’s Herzuma® (biosimilar trastuzumab) approved in Europe||Celltrion Healthcare|
|2016-12-27||Celltrion Healthcare website renewed||Celltrion Healthcare|